{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T21:47:21Z","timestamp":1770414441317,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["16-14-00083"],"award-info":[{"award-number":["16-14-00083"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.antiviral.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T03:12:56Z","timestamp":1517973176000},"page":"18-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Phage display antibodies against ectromelia virus that neutralize variola virus: Selection and implementation for p35 neutralizing epitope mapping"],"prefix":"10.1016","volume":"152","author":[{"given":"Yana","family":"Khlusevich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrey","family":"Matveev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Baykov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Bulychev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolai","family":"Bormotov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Ilyichev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgiy","family":"Shevelev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"Morozova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitrii","family":"Pyshnyi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nina","family":"Tikunova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2018.02.006_bib1","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1016\/j.vaccine.2014.05.012","article-title":"A protective chimeric antibody to tick-borne encephalitis virus","volume":"32","author":"Baykov","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.antiviral.2018.02.006_bib2","doi-asserted-by":"crossref","first-page":"9458","DOI":"10.1073\/pnas.1233578100","article-title":"Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses","volume":"100","author":"Belyakov","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.antiviral.2018.02.006_bib3","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nbt0202-114","article-title":"Antibodies for defense against biological attack","volume":"20","author":"Casadevall","year":"2002","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib4","first-page":"175","article-title":"Analysis of antibody production to vaccinia virus in man and rabbits in response to inoculation of a recombinant vaccinia-hepatitis B vaccine","volume":"33","author":"Chelyapov","year":"1988","journal-title":"Vopr. Virusol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048706","article-title":"Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies","volume":"7","author":"Crickard","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.antiviral.2018.02.006_bib6","doi-asserted-by":"crossref","first-page":"11724","DOI":"10.1128\/JVI.79.18.11724-11733.2005","article-title":"Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice","volume":"79","author":"Davies","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S1473-3099(03)00856-9","article-title":"Human monkeypox: an emerging zoonosis","volume":"4","author":"Di Giulio","year":"2004","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.02.006_bib8","first-page":"173","article-title":"Construction of combinatorial immune library of single chain human antibodies to orthopoxviruses and selection from this library antibodies to recombinant protein prA30L of variola virus","volume":"41","author":"Dubrovskaia","year":"2007","journal-title":"Mol. Biol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/nm1261","article-title":"Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus","volume":"11","author":"Edghill-Smith","year":"2005","journal-title":"Nat. Med."},{"key":"10.1016\/j.antiviral.2018.02.006_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1574-6976.2000.tb00536.x","article-title":"Adventures with poxviruses of vertebrates","volume":"24","author":"Fenner","year":"2000","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.antiviral.2018.02.006_bib11","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/rmv.506","article-title":"Classic paper: fenner on the exanthemata","volume":"16","author":"Fenner","year":"2006","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/S0140-6736(62)91935-9","article-title":"Antivaccinial gamma-globulin in the control of smallpox","volume":"1","author":"Hobday","year":"1962","journal-title":"Lancet"},{"key":"10.1016\/j.antiviral.2018.02.006_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1086\/422999","article-title":"Clinical efficacy of intramuscular vaccinia immune globulin: a literature review","volume":"39","author":"Hopkins","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.02.006_bib14","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1007\/s007050050461","article-title":"The reactivity of monoclonal antibodies against orf virus with other parapoxviruses and the identification of a 39 kDa immunodominant protein","volume":"143","author":"Housawi","year":"1998","journal-title":"Arch. Virol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1542\/peds.18.2.177","article-title":"Hyperimmune vaccinal gamma-globulin: source, evaluation, and use in prophylaxis and therapy","volume":"18","author":"Kempe","year":"1959","journal-title":"Pediatrics"},{"issue":"7","key":"10.1016\/j.antiviral.2018.02.006_bib300","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1093\/molbev\/msw054","article-title":"MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger datasets","volume":"33","author":"Kumar","year":"2016","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib16","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1128\/JVI.74.7.3353-3365.2000","article-title":"Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo","volume":"74","author":"Lin","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib17","doi-asserted-by":"crossref","first-page":"503","DOI":"10.4269\/ajtmh.2009.80.503","article-title":"Monkeypox or Varicella? Lessons from a rash outbreak investigation in the republic of the Congo","volume":"80","author":"MacNeil","year":"2009","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2018.02.006_bib18","first-page":"325","article-title":"The use of hyperimmune antivaccinia gamma-globulin for the prevention and treatment of smallpox","volume":"27","author":"Marennikova","year":"1962","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.antiviral.2018.02.006_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1005148","article-title":"Structural and functional characterization of anti-A33 antibodies reveal a potent cross-species orthopoxviruses neutralizer","volume":"11","author":"Matho","year":"2015","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.antiviral.2018.02.006_bib100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3851\/IMP1573","article-title":"Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model","volume":"15","author":"McCausland","year":"2010","journal-title":"Antivir. Ther."},{"issue":"2","key":"10.1016\/j.antiviral.2018.02.006_bib20","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1093\/cid\/cit703","article-title":"Human monkeypox","volume":"58","author":"McCollum","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2018.02.006_bib21","series-title":"Fields virology","first-page":"2129","article-title":"Poxviridae","author":"Moss","year":"2013"},{"key":"10.1016\/j.antiviral.2018.02.006_bib22","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/j.1460-2075.1994.tb06308.x","article-title":"Antibody fragments from a \u2018single pot\u2019 phage display library as immunochemical reagents","volume":"13","author":"Nissim","year":"1994","journal-title":"EMBO J."},{"key":"10.1016\/j.antiviral.2018.02.006_bib23","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.1128\/JVI.00115-06","article-title":"Protective immunity against secondary poxvirus infection is dependent on antibody but not on CD4 or CD8 T-cell function","volume":"80","author":"Panchanathan","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib24","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2217\/17460794.3.6.595","article-title":"Therapeutic and prophylactic drugs to treat orthopoxvirus infections","volume":"3","author":"Parker","year":"2008","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib26","doi-asserted-by":"crossref","first-page":"982","DOI":"10.4269\/ajtmh.12-0758","article-title":"Detection of human monkeypox in the republic of the Congo following intensive community education","volume":"88","author":"Reynolds","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.antiviral.2018.02.006_bib27","doi-asserted-by":"crossref","first-page":"16262","DOI":"10.1073\/pnas.1005769107","article-title":"Major increase in human monkeypox incidence 30 years after smallpox vaccination campaigns cease in the Democratic Republic of Congo","volume":"107","author":"Rimoin","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.antiviral.2018.02.006_bib28","doi-asserted-by":"crossref","first-page":"5020","DOI":"10.1128\/JVI.02933-15","article-title":"The vaccinia virus H3 envelope protein, a major target of neutralizing antibodies, exhibits a glycosyltransferase fold and binds UDP-glucose","volume":"90","author":"Singh","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib29","first-page":"20","article-title":"Human recombinant antibodies to variola virus","volume":"50","author":"Tikunova","year":"2005","journal-title":"Vopr. Virusol."},{"key":"10.1016\/j.antiviral.2018.02.006_bib30","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.virusres.2011.09.008","article-title":"The neutralizing human recombinant antibodies to pathogenic Orthopoxviruses derived from a phage display immune library","volume":"163","author":"Tikunova","year":"2012","journal-title":"Virus Res."},{"issue":"1","key":"10.1016\/j.antiviral.2018.02.006_bib200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3851\/IMP1717","article-title":"Protective murine and human monoclonal antibodies against eczema vaccinatum","volume":"16","author":"Tomimori","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2018.02.006_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/0042-6822(86)90405-8","article-title":"Identification of antigenic determinants by polyclonal and hybridoma antibodies during the course of infection by vaccinia virus","volume":"148","author":"Wilton","year":"1986","journal-title":"Virology"},{"key":"10.1016\/j.antiviral.2018.02.006_bib32","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.antiviral.2018.02.006_bib33","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1128\/JVI.65.11.6101-6110.1991","article-title":"Vaccinia virus morphogenesis is interrupted when expression of the gene encoding an 11-kilodalton phosphorylated protein is prevented by the Escherichia coli lac repressor","volume":"65","author":"Zhang","year":"1991","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217306964?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354217306964?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T20:34:24Z","timestamp":1660422864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354217306964"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":35,"alternative-id":["S0166354217306964"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.02.006","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phage display antibodies against ectromelia virus that neutralize variola virus: Selection and implementation for p35 neutralizing epitope mapping","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}